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ABSTRACT
The glucocorticoid receptor (GR) is a ligand activated
transcription factor, serving to regulate both energy
metabolism and immune functions. Factors that influ-
ence cellular sensitivity to glucocorticoids (GC) are
therefore of great interest. The N-terminal of the GR
contains numerous potential proline-directed phos-
phorylation sites, some of which can regulate GR
transactivation. Unrestricted proline isomerisation
can be inhibited by adjacent serine phosphorylation
and requires a prolyl isomerise, Pin1. Pin1 therefore
determines the functional outcome of proline-
directed kinases acting on the GR, as cis/trans
isomers are distinct pools with different interacting
proteins. We show that Pin1 mediates GR transacti-
vation, but not GR trans-repression. Two N-terminal
GR serines, S203 and S211, are targets for Pin1 po-
tentiation of GR transactivation, establishing a direct
link between Pin1 and the GR. We also demonstrate
GC-activated co-recruitment of GR and Pin1 to the
GILZ gene promoter. The Pin1 effect required both
its WW and catalytic domains, and GR recruitment
to its GRE was Pin1-dependent. Therefore, Pin1 is a
selective regulator of GR transactivation, acting
through N-terminal phospho-serine residues to
regulate GR recruitment to its target sites in the
genome. As Pin1 is dysregulated in disease states,
this interaction may contribute to altered GC action
in inflammatory conditions.
INTRODUCTION
Glucocorticoids (GCs) are highly potent anti-inﬂammatory
agents but also exert important effects on carbohydrate
metabolism, resulting in off-target phenomena including
diabetes and obesity. Therefore, there is considerable
interest in identifying how the broad spectrum of gluco-
corticoid activities can be targeted, to retain the beneﬁcial
anti-inﬂammatory actions, but minimize metabolic off-
target effects. Glucocorticoids act through the glucocortic-
oid receptor (GR), a member of the nuclear receptor
superfamily. The GR undergoes extensive post-transla-
tional modiﬁcation in response to both ligand binding
and also activation of cellular stress pathways (1). The
best characterized modiﬁcations lie in the N-terminal
domain, and consist of proline-directed serine phosphoryl-
ation sites. For some target genes, the importance of indi-
vidual modiﬁcations has been deﬁned, e.g. transactivation
of IGFBP1 requires phosphorylation of serine 211 (S211),
and thereby recruitment of the co-activator MED14
(2). Some GR phosphorylation sites have been shown to
enhance, for example, S211 and S203 (3), whereas others
inhibit GR transactivation, for example, at S226 (4) and
S404 (5) [reviewed in (6)].
Proline can adopt either a cis or trans conformation and
is typically found on the solvent-accessible surface of
proteins. Proline isomerisation therefore offers a molecu-
lar switch for recruitment of protein binding partners
and with the slow intrinsic timescale of spontaneous
isomerisation results in essentially separate ‘pools’ of
isomers. Serine or threonine phosphorylation essentially
prevents spontaneous isomerization at adjacent proline
residues (pS/T-P), which then requires isomerization by
Pin1 (7). Pin1 is only able to isomerise phosphorylated
S/T-P motifs (8). This is important as both kinases and
phosphatases acting on these pS/T-P sites require a trans-
proline isomer. Therefore, the GR phosphosites at both
S203 and S211 are potential Pin1 targets, raising the pos-
sibility that Pin1 is an important mediator of GR function.
Interestingly, post-phosphorylation regulation of protein
function now appears to be important for many cellular
processes and diseases, including neurodegeneration (9),
lipid metabolism (10) and activation of the toll-like
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receptor pathways (11). The Pin1 knockout mouse has a
mild phenotype, similar to the cyclin D1 knockout (12), a
phenotype predicted as Pin1 is required for stable cyclin
D1 expression, through action on b-catenin (13).
Pin1 expression is augmented in both cancer (14–16)
and inﬂammation (17), two pathophysiological states
associated with altered GR function (17), and associates
with other nuclear hormone receptors (NHRs) including
the androgen receptor (18), estrogen receptor (19), Nur77
(20), PPARg (21) and retinoic acid receptor (22). In each
case, Pin1 binds to and regulates the stability of the
receptor. In addition, the steroid co-activator protein 3
(SRC3), important for ER and PR, was also found to
be partly dependent on Pin1 (23).
As Pin1 has been shown tomodulate several NHRs and is
regulated in both inﬂammation and cancer, we investigated
its role in glucocorticoid action. Sequence analysis revealed
a number of possible Pin1 target sequences within the GR
N-terminus, suggesting a possible directmode of action.We
found that GR transactivation, but not trans-repression,
was dependent on Pin1. Indeed, both GR and Pin1 were
found to be recruited to target gene enhancers in response to
GC, and co-immunoprecipitation revealed direct inter-
action between the two proteins. Targeted mutation of
GR at either the S203 or S211 Pin1 sites rendered the GR
independent of Pin1 action. Recruitment of GR to target
enhancers was found to be Pin1 dependent, and this
required an intact Pin1 WW domain, which is responsible
for phospho-protein binding. As Pin1 had previously been
shown to regulate SRC3 function, we determined that the
target genes analysed were not regulated by SRC3. Taken
together, we demonstrate a role for Pin1 in selectively
regulating GR transactivation and thereby promoting
recruitment to target sites in the genome to enhance trans-
activation. The increased expression of Pin1 in inﬂamma-
tion and in cancer is therefore predicted to selectively
enhance GR transactivation, with consequences for cell
function in that environment.
MATERIALS AND METHODS
Materials
Protease inhibitor cocktail (Complete Ultra), Proteinase K
and PhosSTOP were from Roche. PCR puriﬁcation kit
was from Qiagen. siRNA against Pin1 (s10544 and
s10545) and SRC-3 (s15698) were from Life
Technologies and control siRNA (D-001810-03-05) and
Pin1 (ON-TARGETplus SMARTpool, Pin1 L-003291-
00-0005) from Dhamacon. Bradford Protein Assay
(Coomassie Plus) (Thermo Scientiﬁc); Novex SDS-page
kit and Reagents [4–12% bis-tris gels, Lithium dodecyl
sulfate (LDS)-sample buffer], Dynal protein A/G beads,
Optimem, Lipofectamine RNAiMax were from Life
Tecnologies. Juglone was from Merckbiosciences. Halo-
tag puriﬁcation and detection kit, ReliaPrep RNA extrac-
tion kit, DNase I, protease inhibitor cocktail, GoScript
and GoTaq were all from Promega. All other materials
were from Sigma-Aldrich. See Supplementary Methods
for further details of the antibodies and PCR primers
(Euroﬁns MWG Operon) used in this study.
Generation of halo-tag proteins
The GR halo-tag plasmid, pFN21AB9466 N-terminal
Halo-tag vector, was purchased from Promega. Site-
directed mutagenesis was performed using the Quik
change kit (Agilent Technologies). See Supplementary
Methods for details of PCR primers.
Cell culture and transfections
A549 and HEK293T cells were obtained from the Health
Protection Agency Culture Collection; both cell lines
were grown in high glucose DMEM containing 10%
foetal calf serum. siRNA transfections were carried
using Lipofectomine siRNAmax with 10 nM of each
siRNA in Optimem. All other transfections were carried
out using Fugene 6; plasmids were used at 2.5 mg per
10 cm3 of cell culture area.
Cell lysis and immunoprecipitation
Following cell treatments, A549 cells were washed twice in
PBS before being resuspended into lysis buffer [modiﬁed
from (24)] containing the following: 250mM NaCl,
20mM Bicine (pH 7.4), 1 mM CaCl2, 1 mM ZnCl2, 3mM
MgCl2, 0.5% IGEPAL, protease and phosphatase inhibi-
tors. Cell extracts were DNase treated for 15min and
cleared by centrifugation. Protein quantiﬁcation was
carried out using the Bradford assay and BSA as a
standard. Immunoprecipitations were carried out on
500 mg of total protein with 2 mg of antibody for 1 h at
4C, immunocomplexes were captured using Protein A
or G for 30min. Complexes were washed in lysis buffer
6 times before being resuspended in 19.5ml of lysis buffer,
3 ml of DTT (1M) and 7.5 ml of NuPage LDS sample
buffer. Seven percent of the input was used as a compari-
son to the immunoprecipitate sample.
Western blotting
Western blotting was carried using the Nupage system
(Life Technologies) according to the manufacturer’s
instructions. Nupage MES running buffer was used
throughout. Antibodies (see Supplementary Methods)
were used at 1:1000 in Tris-buffered saline [150 mM
NaCl and 20mM Tris (pH 7.5)] with 0.1% Tween-20
(TBST) and 5% non-fat milk powder. Immunoblots were
incubated overnight at 4C. Following three washes in
TBST, immunoblots were incubated with anti-mouse or –
rabbit horseradish peroxidase (HRP)-linked secondary
antibodies (used at 1:10 000) for 1 h. Following three
further washes, immunoreactive bands were visualized
using ECL (Thermo Scientiﬁc).
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) protocols were
modiﬁed from on previously published methods (25,26).
Cells (107) were stimulated with 100 nM dexamethasone
(DEX) for 45min and then ﬁxed with 11 formaldehyde
(50mM Bicine-KOH at pH 8; 1mM EDTA; 0.5mM
EGTA; 100mM NaCl; 11% formaldehyde) for 10min.
Cross-linking was stopped by the addition of glycine to
a ﬁnal concentration of 125mM for 5min. Cells were then
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washed in PBS (600 g for 5min at 4C), before 1ml of
lysis buffer (50mM Bicine-KOH at pH 8; 1mM EDTA;
0.5mM EGTA; 85mM KCl; 10% glycerol; 0.5%
IGEPAL; protease and phosphatise inhibitors) was
added and incubated for 10min at 4C. The crude nuclei
were collected by centrifugation (600 g for 5min at 4C).
Nuclear extracts were re-suspended in 1ml of wash buffer
(10mM Tris–HCl at pH 8; 1mM EDTA; 0.5mM EGTA;
200mM NaCl; protease inhibitor cocktail) and
centrifuged at 600 g for 5min. In all, 0.6ml of RIPA
buffer (10mM Tris–HCl at pH 8; 1mM EDTA; 0.5mM
EGTA; 140mM NaCl; 1% Triton X-100; 0.1% sodium
deoxycholate; 0.1% SDS; protease inhibitors) was added
to the nuclear pellets. Samples were sonicated (using a
probe sonicator at 30% power) for 30 s bursts followed
by 30 s of cooling on ice for a total sonication time of
3min per sample (producing 1000–500 bp fragments).
Samples were centrifuged at 16 000 g for 10min at 4C.
Two micrograms of antibody was added to cleared chro-
matin extract and incubated with rotation at 4C over-
night (50 ml retained for input). Samples were then
centrifuged again, and supernatants were transferred to
fresh tubes containing pre-washed (in RIPA) protein A
or G Dynal beads (10 ml in 100 ml of RIPA buffer) and
incubated for 1 h. The beads were washed twice with
RIPA buffer and once with RIPA buffer containing
250mM NaCl. Hundred microlitres of digestion buffer
was added (50mM Tris at pH 8; 1mm EDTA; 300mM
NaCl; 0.5% SDS; 100 mg/ml proteinase K) and placed at
55C for 3 h and then for 95C for 15min. Samples were
puriﬁed using a PCR puriﬁcation kit (eluted in 20 ml).
qPCR was performed on 5 ml of each sample and ex-
pressed a percentage of the input sample (27).
qPCR and reporter gene assays
RNA was extracted from A549 cells using the Rellia prep
RNA extraction kit according to the manufacturer’s
instructions. qPCR was performed using the GoScript
transcription system and the GoTaq qPCR master mix.
qPCR was carried out using the StepOne Plus real time
PCR system and then analysed using the StepOne
software V2 (using the comparative CT method and
Rpl19 as a house-keeping gene). See Supplementary
Methods for qPCR primers. A549 cells were transfected
as described earlier in the text with Pin1 siRNA, Halo-GR
(WT and serine/proline mutants) and MMTV-luciferase
(with Renilla-CMV to normalize for differences in trans-
fection efﬁciency) in 10 cm3 plates. Sixteen hours later,
cells were replated into 12-well plates. DEX was added
6 h before luciferase was measured.
Halo-tag ChIP system
Halo-tag proteins were expressed as in A549 cells in
10 cm3 plates. Cells were serum starved for 6 h and then
stimulated with DEX (100 nM) for 30min. The media was
removed, and the cells were washed twice in cold PBS.
Five hundred microlitres of Halo-cytoplasmic lysis
buffer [85mM KCl, 10mM Bicine (pH 7.4), 1%
IGEPAL and protease inhibitor cocktail]. Lysates were
centrifuged at 700 g for 5min and then resuspended in
600 ml of buffer consisting of 150mM NaCl, 10mM Tris
[pH 7.5] 1% triton 100, 0.5% deoxycholate (w/v) and
sonicated as described earlier in the text. Two hundred
microlitres Halo link resin was pre-washed in TBS supple-
mented with 0.05% IGEPAL. Following an overnight in-
cubation, the resin was washed in lysis buffer, high salt
buffer (lysis buffer with 500mM NaCl) and then 2H2O.
Hundred microlitres of digestion buffer was added and
prepared as described earlier in the text.
Statistical analysis
Statistical analysis was performed using SPSS v16, multiple
comparisons were analysed using a one-way analysis of
variance (ANOVA) or univariate general linear model
(GLM) with a Bonferroni post-hoc test. Non-parametric
data were analysed using a Kruskal–Wallis one-way
analysis of variance.
RESULTS
The effect of Pin1 inhibition on GR trans-activation and
trans-repression
Pin1 recognizes phosphorylated serine residues, which
results in cis/trans isomerization of proline peptide
bonds in a consensus ﬂanking amino acid context
(Figure 1A). A number of such candidate motifs lie
within the GR N-terminal domain (Figure 1B). Pin1-
binding sites have been well documented in other
members of the NHR family, shown as sequence fre-
quency logo (Figure 1C), based on peptide sequences
from the androgen receptor (18), estrogen receptor (19),
PPARg (21), PML (29) and Nur77[TR3 (30,31)].
Initial studies used the Pin1 inhibitor juglone to screen
for Pin1 effects on GR transactivation (Supplementary
Figure S1). Juglone exerted a dose-dependent inhibitory
effect on multiple GR transactivation targets, but did not
affect basal expression of these genes. Pin1 knockdown
was then used, and again a signiﬁcant loss of transactiva-
tion (P< 0.05) was seen (Figure 2A–E and Supplementary
Figure S2). Glucocorticoid treatment itself did not
regulate Pin1 expression (Figure 2F–G).
Using an NFkB reporter gene assay, the effect of Pin1
on GR-trans-represson was determined (Figure 3A).
Knockdown of Pin1 expression, with siRNA, resulted in
impaired tumour necrosis factor (TNF) induction of the
reporter, but juglone did not show this effect, possibly
reﬂecting cellular adaptations to prolonged loss of Pin1
protein (Figure 3A and B). However, GC inhibition was
unaffected by Pin1 disruption in either case (Figure 3A
and B). Analysis of the endogenous TNF target genes
IL-6 and IL-8 also revealed reduced TNF induction
under conditions of Pin1 knockdown, but again GC re-
pression was unaffected (Figure 3C and D). Similar results
were seen with lipopolysaccharide (LPS) induction of the
cytokines IL-6 and IL-8 (Supplementary Figure S3).
The effect of Pin1 on GR phosphorylation and stability
We observed loss of the characteristic rapid GR-S211
phosphorylation in response to GC activation both
with Pin1 siRNA, and also antagonism with juglone
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(Figure 4A and B), suggesting a role for Pin1 in acquiring
or maintaining the phospho mark. Translocation of the
GR to the nucleus, a critical regulatory step in gene regu-
lation, was unaffected by Pin1 knockdown (Figure 4C),
and there was no discernible effect on GR protein abun-
dance, either under basal conditions or following ligand
activation (Figure 4D). Attempts to discern differences in
GR protein stability in the absence of Pin1, analogous to
that seen for cyclin D1, did not reveal any signiﬁcant dif-
ferences (Figure 4E and Supplementary Figure S4). GR
and Pin1 were also found in the same molecular complex
as demonstrated using a co-immunoprecipitation
immunoblot (Figure 5A and B). The strength of the inter-
action appeared to be enhanced by ligand activation, as
demonstrated in the GR immunoprecipitation
(Figure 5B).
The Pin1 domains required for recognising phosphory-
lated residues, or catalysing isomerisation were then
targeted, by mutation to Y23A (in the WW-domain) or
C113A (in the catalytic domain) (Figure 5C and D). Both
of these mutations have been shown to hinder Pin1
binding to target substrates (21,32,33). Wild-type and
mutant Pin1 molecules were all expressed at a similar
level (Figure 5C), but neither Y23A, nor C113A were
able to potentiate GR transactivation (Figure 5D).
To prove a functional effect of Pin1 directly on the GR,
rather than through intermediary proteins, two GR
mutants were constructed each of which contained a
phosphomimetic aspartate at 203, or 211, and a glutamine
in place of the adjacent proline (S203D-P204Q and
S211D-P212Q). Mutations to these residues result in a
phosphomimetic GR, but one not recognised by Pin1,
as previously demonstrated (21). These mutant GR
molecules showed variable effects on ligand-induced
transactivation, with S203D-P204Q attenuated, and
S211D-P212Q enhanced, but more importantly, both
were unaffected by loss of Pin1 expression (Figure 5E
and F). As an additional control, we mutated GR S404
(S404D-P405Q). GR S404D-P405Q showed enhanced
transactivation but retained Pin1 regulation (Figure 5E
and F).
Pin1 effects on GR transactivation do not require SRC-3
Previous reports have shown that Pin1 can act on the
nuclear receptor co-activator SRC-3 (23). Although we
Figure 1. Proline-directed phosphorylation sites in the GR. (A) Pin1 sites binds to pS/T-P sites [e.g. WFYpSPR (8)]; cis/trans isomerization at pS/T-
proline sites is reduced by phosphorylation (7), but is then a target for Pin1, which catalyzes cis/trans isomerization at pS/T-P motifs. (B) The major
phosphosites found in the N-terminal region of GR (28). The majority of phosphosites in GR are proline-directed S/T-P sites. Some of these sites
have been shown to be required for transactivation (S203 and S211), whereas some have shown to have a negative effect on GR activation (S226 and
S404). Eight of the major proline-directed GR sites were used to create the sequence logo (28). (C) Pin1 recognition sites [taken from (28) previously
found in nuclear receptors: androgen receptor (18) estrogen receptor (19), PPARg (21), PML (29) and Nur77(TR3 (30,31)] were used to generate a
sequence frequency logo (28).
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showed that the Pin1 effect on GR was dependent on
phosphoserines in the N-terminal domain, and not the
site of interaction between GR and the SRC family of
co-activators in the C-terminal domain, additional
studies were focussed on a potential role for SRC-3.
GR functions have been shown to be independent of
SRC-3, whereas SRC-2 is an important co-regulator
(34). Moreover, when we examined the role of SRC-3 in
mediating transactivation by GR, we found no effect on
our principle index gene GILZ (Figure 5G and
Supplementary Figure S5 for siRNA knockdown of
SRC-3). Although GR and SRC-2 interact (35), there
was no interaction seen between Pin 1 and SRC-2
(Figure 5G).
Pin1 on GR recruitment to the promoter DEX-responsive
genes
The data aforementioned suggested a speciﬁc loss of GR
transactivation function that was dependent on Pin1
action on the proline-directed serine phosphorylation
sites at GR S203 and S211. Using the GILZ GRE as a
well-validated target for GR binding, ChIP analysis
revealed GC induction of GR recruitment, as expected
(Figure 6A). In addition, there was induction of Pin1
binding to the same sequence in response to GC
(Figure 6A). Knockdown of Pin1 dramatically attenuated
GR recruitment (Figure 6B, C). We also determined
effects of Pin1 siRNA on the levels of H3K9 acetylation
Figure 2. Pin1 inhibition impairs GR transactivation. A549 cells were transfected with control or Pin1 siRNA, incubated for 48 h and then
stimulated with 1 or 100 nM DEX for 2 h. GC-responsive genes were measured by qPCR (A) IP6K3, (B) GILZ, (C) hIAP, (D) IGFBP1, (E)
FKBP5. (F) Pin1 gene expression was also determined to demonstrate the effect of the siRNA. Graphs show mean (±SD) fold change in gene
expression compared with controls (RQ). Statistical signiﬁcance was determined using a one-way ANOVA with a Bonferroni post-hoc test
(P< 0.05*) to determine the effect of Pin1 (n=7 for GILZ and Pin1, all other genes, n=3).
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at the GILZ promoter (Supplementary Figure S6),
showing a signiﬁcant reduction. To determine whether
the Pin1 effect on GR recruitment was dependent on the
Pin1 WW domain, which recognizes the phosphorylated
serine residues, we used the point mutated Pin1 (Y23A)
characterized earlier in the text (Figure 5C and D). The
mutant Pin1 was not recruited to the GILZ promoter, in
contrast to wild-type Pin1 (Figure 6D). Using the Pin1
C113A, which disrupts the catalytic domain and
provides a dominant negative effect, we also see an inhibi-
tory effect on GR recruitment to the GILZ GRE
(Figure 6E). To conﬁrm these effects are seen at other
GR binding sites, we analysed the MTIX gene GRE and
found similar enrichment of Pin1 (Figure 6F) and GR-
dependence for GR transactivation (Supplementary
Figure S2).
DISCUSSION
The GR has a broad spectrum of activities, regulating
energy metabolism, and also the immune response. The
ligand activated GR can both transactivate and trans-
repress target gene expression, and though multiple mech-
anisms have been described, the precise explanation of
how the same molecule can exert opposing effects on
gene expression remains unclear (36). In addition, a
major puzzle is how cells and tissues can vary their sensi-
tivity to glucocorticoids, despite the near ubiquitous
expression of the GR.
In particular, acquired resistance to the action of GCs in
inﬂammation is common, with a number of contributing
factors proposed, including cross-talk from other pro-
inﬂammatory signalling pathways, for example, mediated
by TNF and interferon (35) or histone deacetylase enzymes
(37,38). GR is subjected to numerous post-translational
modiﬁcations, including phosphorylation (39),
ubiquitination (40) and sumoylation (41), some of which
have been shown to contribute to resistance states (42). The
majority of the phosphorylation sites on GR are proline-
directed (S/T-P), which opens up the possibility that the
prolyl-isomerase, Pin1, could regulate GR function.
Furthermore, Pin1 expression is upregulated in inﬂamma-
tion and is reported to inﬂuence pro-inﬂammatory
signalling (11). The phenotype of the Pin1 knockout
mouse is complex, with premature aging, tauopathy and
neurodegeneration [reviewed in (43,44)], insulin resistance
(45) and also increased sensitivity to LPS challenge (46).
The GR contains a number of candidate Pin1 recogni-
tion sequences in its N-terminal domain, two of which,
S203 and S211, have previously been shown to be
induced by ligand binding and to be required for
maximal transactivation on some DNA templates. Initial
Figure 3. Pin1 is not required for GR trans-repression. A549 cells were treated with juglone for 1 h transfected with control or Pin1 siRNA and
incubated for 48 h. Cells were then stimulated with TNFa (0.25 ng/ml) with 1 or 100 nM DEX. Cells were incubated for 16 h before the levels of
NRE-luciferase (A and B) or TNFa-responsive genes (n=3 for each) (C). IL-6 and (D). IL-8 were determined by qPCR. Graphs show mean (±SD)
fold change in gene expression compared to controls (RQ). Statistical signiﬁcance was determined using a GLM procedure determine the interaction
between DEX and Pin1 (P> 0.05) on repression of TNFa-responsive genes (n=3 for IL-6 and IL-8).
6 Nucleic Acids Research, 2013
 at U
niversity of M
anchester on M
ay 13, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
screening with the Pin1 inhibitor juglone revealed a major
loss of GR transactivation, but negligible impact on GR
trans-repression. This dissociation of GR function was of
interest, as many of the beneﬁcial anti-inﬂammatory
actions of GCs come at the price of off-target gene trans-
activation (47). However, the non-speciﬁc effects of
juglone are well documented, including effects on RNA
polymerase II (48–51). Therefore, siRNA was optimized
for knockdown of Pin1 protein in subsequent analyses.
These revealed, again, a profound loss of GR transactiva-
tion but little impact on trans-repression.
Previous reports have determined which regulatory
surface of the GR molecule is required for speciﬁc gene
activation. For example, hIAP is thought to be dependent
on an intact N-terminal domain, as is IGFBP1 (which is
also requires the recruitment of MED14 complexes).
Other genes, such as GILZ or IP6K3 are thought to be
independent of the N-terminal domain (52), which
includes the proline-directed phospho-serine sites.
However, we discovered that both GILZ and IP6K3
were sensitive to Pin1 inhibition. This suggests that Pin1
may be acting in a way that permits both N- and C-
terminal transactivation domains to be operational, such
as affecting GR recruitment to its GRE sites in the
genome. In contrast, GR trans-repression of NFkB
driven genes is classically thought to occur through a
tethering mechanism, and we did not detect any effect of
Pin1 on this mode of action. SRC-2 is a co-modulator
protein for GR that both activates and represses target
genes (36,53); however, we did not ﬁnd Pin1bound to
SRC-2, in contrast to the previously reported association
between Pin1 and SRC-3 (23).
As Pin1 has been shown to regulate the stability of some
target substrate proteins, both in a positive and negative
direction, we studied Pin1 effects on GR expression, sta-
bility, trafﬁcking and phosphorylation. Essentially, there
was no discernible effect of Pin1 loss on any of these
aspects of GR, but consistent decreases in ligand activated
S211 phosphorylation were observed. As S211 phosphor-
ylation is required for maximal transactivation of some
(IGFBP1), but not all (IP6K3) target genes, this was of
interest. However, as the detection of S211 phosphoryl-
ation required an antibody, we could not exclude the
possibility that loss of Pin1 exerted an effect on the cis/
trans isomer balance and thus affected a conformational
epitope. The kinases responsible for ligand-activated
phosporylation of S203 and S211 remain obscure, but
evidence has been presented for both cyclin-dependent
kinases (CDKs) and mitogen-activated protein kinases
(MAPKs). Such kinases require the trans isomer to be
an effective substrate, and the balance between cis and
trans is determined by Pin1 action. Therefore, Pin1 regu-
lates the outcome of the kinase(s) acting at these two
serines.
As previous reports had revealed Pin1 isomerization of
SRC-3 as important for regulating ER transactivation, we
sought evidence that the Pin1 effect was targeted to the GR
itself. First, we were able to show that SRC-3 was not
required for GR transactivation of the GILZ gene,
although Pin1 was required. Second, we showed that
Figure 4. The effect of Pin1 inhibition on GR phosphorylation, nuclear translocation and stability. (A) A549 cells were transfected with Pin1 or
control siRNA for 48 h. Cells were then treated with 1 or 100 nM for 30min. Immunoblots were probed for phospho- GR (S211), GR, Pin1 and
tubulin. (B) Cells were pre-treated with juglone for 30min before a 30-min treatment of 100 nM DEX. (C) A549 cells were pre-treated with juglone
(30 mM) for 30min before a 30-min treatment with 100 nM DEX. Cytosol and nuclear fractions were prepared, and subsequent immunoblots were
probed for GR and Histone H1. (D) A549 cells were transfected with Pin1 or control siRNA for 48 h before being stimulated with DEX (100 nM) or
4 or 8 h, whole-cell extracts were probed for GR and Pin1. (E) A549 cells were transfected with Pin1 siRNA as described in (D), cycloheximide
(50 mg/ml) was added to the cells for 4, 8 and 16 h, subsequent immunoblots were probed for GR, Pin1 and b-actin.
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targeted mutations to the GR, to prevent S203 and S211
phosphosite recognition by Pin1, resulted in competent GR
transactivation, but were now independent of Pin1 effect.
Taken together, these data support a role for Pin1 acting on
the GR to modify its function, strengthened by ﬁnding
Pin1/GR interaction in co-immunoprecipitation studies.
Further analysis of the Pin1 GR interaction revealed
that disruption to the Pin1 proline-directed serine recog-
nition site (WW domain) abolished the co-activation
effect. We showed that ligand-activated GR binding to
the well-characterised GILZ gene GRE was accompanied
by recruitment of Pin1, and reciprocally, that loss of Pin1
attenuated GR binding. This suggested a role for Pin1-
directed GR isomerization in promoting GR interaction
with the genome, speciﬁcally to sites required for GR
transactivation (36). To investigate this in more detail,
we showed that mutations to the Pin1 WW domain,
which blocked GR co-activation, also result in loss of
Pin1 recruitment to the GRE, excluding a scaffold
effect, and identifying a requirement for phospho-serine
recognition. A further mutation to Pin1 (C113A), which
disrupts the isomerase catalytic domain, was also shown
to inhibit GR recruitment to the GRE, strengthening the
mechanistic link requiring Pin1 action on the GR to
permit efﬁcient DNA binding.
Taken together, we have identiﬁed a master-regulator
role for Pin1 on GR signalling. Pin1 is required
for full transactivation, but not trans-repression of
Figure 5. Pin1 interactions with the GR. (A) A549 cells were stimulated with DEX (100 nM) for the indicated time, Pin1 was immunoprecipitated
from cell lysates and immunoblots probed for GR (dashed line represents a different exposure for input). (B) Reciprocal immunoprecipitaions for
GR. Seven percent of the input sample was used in the immunoblot. (C) Expression of Halo-Pin1 mutants and their location in Pin1. pHalo (pHT),
pHT-Pin1 WT, pHT-Pin1 Y23A and pHT-Pin1 C113A expression in A549 cells. (D) A549 cells were transfected with WT Pin1, Pin1 Y23A, Pin1
C113A and MMTV-luc for 16 h, after which DEX 1-500 nM was added for 6 h. (E) A549 cells were transfected with Pin1 siRNA for 48 h, after 24 h
cells were transfected with a MMTV-luciferase reporter. In all, 10 nM DEX was added for 6 h (n=6). (F) HEK293T cells were transfected with
control or Pin1 siRNA for 16 h followed by transfection with MMTV-luciferase reporter and Halo-tag GR WT, S203D-P204Q, S211D-P212Q or
S404D-P405Q. Cells were then pre-treated with 10 nM DEX for 6 h. Graphs show mean (±SD) of the normalized fold change in MMTV promoter
activity (n=3). (G) A549 cells were treated with DEX for 1 h, cell lysates were prepared and SRC-2 or Pin1 immunoprecipitated and immunobloted
with either SRC-2 or Pin1 antibodies. A549 cells were treated with SRC-3 siRNA for 48 h and treated with DEX for 2 h before the levels of the
GILZ gene were determined by qPCR (n=3). Statistical analysis was determined using a one-way ANOVA and a Bonferroni post-hoc test
(P< 0.05*).
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NFkB-activated genes. In contrast to the actions of Pin1
on other nuclear receptors, we have not found effects on
GR stability or a requirement for modiﬁcation of the SRC-
3 co-activator to explain altered GR activity. However, we
did ﬁnd evidence for GR-Pin1 binding, both at the
protein–protein level, and also in later studies using
ChIP binding for both proteins to a GRE element
upstream of the GILZ gene. We show a role for Pin1 in
regulating GR binding to its GRE, thereby offering an
explanation for the requirement of Pin1 for maximal GR
transactivation. The Pin1 effect required an intact WW
domain, required for binding phosphorylated serines,
and also proline-directed serine phosphorylation of the
GR. As Pin1 is regulated in inﬂammatory and malignant
disease, we predict a selective alteration in GR function
would be a consequence, as has recently been deﬁned
(36). Moreover, targeting the Pin1 effect on GR may
offer a means to focus GR activity towards anti-inﬂamma-
tory circuits and away from effects on energy mobilization.
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